The life sciences company is developing pro-biotic compounds that tackle obesity, high cholesterol and diabetes.
Key among the deals inked was one with Tata Chemicals to develop weight management products containing its SlimBiome additive for the Indian market.
Sacco deal inked
It also has a profit-sharing deal with Italian firm Sacco to manufacture and supply OptiBiotix's cholesterol-reducing strain, LPLDL. The first sales of this particular product were made to HLH BioPharma Vertriebs.
At the same time it has a non-exclusive agreement with Nutrilinea for the production and commercialisation of products containing the LPLDL in Europe.
Deals with Sacco and HLH, meanwhile, have been expanded since the period-end.
The financial performance of the company was positively impacted by the spin-off earlier this year of subsidiary Skinbiotherapeutics as a separate AIM-listed company valued at £4.5mln.
This resulted in a change in value of Opti’s investment in the business of £4.1mln. This adjustment led to the company posting a pre-tax profit of £3.2mln for the six months ended May.
Chief executive Stephen O’Hara was upbeat on what was achieved as well as the prospects for remainder of the financial year.
"OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base,” he said in a statement.
“This has stimulated industry interest from both national and multinational companies in selling our products in both consumer health and pharmaceutical markets around the world.
“The microbiome has been described by commentators as healthcare's 'most promising and lucrative frontier'.
“As OptiBiotix's microbiome modulating platforms generate products and multiple revenue streams from royalties and supply agreements, there is potential for a significant enhancement in the value of the company.”